Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCQARM)

• Drug Name: TTP889 Drug Info
• Synonyms: VP-14637; VP 14637; 235106-62-4; (E)-2,2'-((4-hydroxyphenyl)methylene)bis(4-((E)-(5-methyl-1H-tetrazol-1-ylimino)methyl)phenol); MDT-637; AC1O5AXS; CHEMBL3393516; SCHEMBL20741449; SCHEMBL16743389; CHEMBL3393661; (4E)-2-[(4-hydroxyphenyl)-[(3E)-3-[[(5-methyltetrazol-1-yl)amino]methylidene]-6-oxocyclohexa-1,4-dien-1-yl]methyl]-4-[[(5-methyltetrazol-1-yl)amino]methylidene]cyclohexa-2,5-dien-1-one; DB12195; ACM235106624; J-015135

Indication

Disease Entry	ICD 11	Status	REF
Blood forming organ disorder	JB64.1	Phase 2	[1]
Respiratory syncytial virus infection	1C80	Terminated	[2]

• Cross-matching ID:
  PubChem CID: 135484065
  CAS Number: CAS 235106-62-4
  TTD Drug ID: DMCQARM

Molecule-Related Drug Atlas

Drug(s) Targeting Measles virus Fusion glycoprotein (MeV F)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MLN1202	DM24SOL	Metastatic cancer	2D50-2E2Z	Phase 2	[2]
AMG 876	DM1FJ9C	Type-2 diabetes	5A11	Phase 1	[3]
AC 165198	DMS3915	Diabetic complication	5A2Y	Phase 1	[4]

Drug(s) Targeting Coagulation factor IX (F9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[5]
Recombinant Factor IX	DMY7ESM	Bleeding disorder	GA20-GA21	Approved	[6]
CSL-654	DMZJGVL	Factor IX deficiency	3B11	Phase 3	[7]
RG6013	DMER75Y	Haemophilia A	3B10.0	Phase 3	[8]
AMT-061	DMSO02K	Haemophilia B	3B11.0	Phase 3	[9]
Fidanacogene elaparvovec	DMFZ81T	Haemophilia B	3B11.0	Phase 3	[10]
Mim8	DMX33ZR	Haemophilia A	3B10.0	Phase 3	[11]
AMT-060	DM7RNKM	Factor IX deficiency	3B11	Phase 1/2	[12]
SB-FIX	DMUP52Y	Haemophilia B	3B11.0	Phase 1/2	[13]
AAV2-hFIX16	DMIDEKB	Factor IX deficiency	3B11	Phase 1	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor IX (F9)	TTFEZ5Q	FA9_HUMAN	Inhibitor	[1]
Measles virus Fusion glycoprotein (MeV F)	TTUPB12	FUS_MEASC	Inhibitor	[2]

References

• [1] Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63.
• [2] Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17.
• [3] Clinical pipeline report, company report or official report of Amgen.
• [4] WO patent application no. 2013,1306,83, Xten conjugate compositions and methods of making same.
• [5] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [6] BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B. Ther Adv Hematol. 2014 Oct;5(5):168-80.
• [7] Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012 September 20; 120(12): 2405-2411.
• [8] Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014 Feb;12(2):206-13.
• [9] Clinical pipeline report, company report or official report of uniQure.
• [10] Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost. 2021 May;19(5):1212-1218.
• [11] ClinicalTrials.gov (NCT05878938) Open-label Safety Study in Adults and Adolescents With Haemophilia A With and Without FVIII Inhibitors Switching Directly From Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis. U.S.National Institutes of Health.
• [12] Phase I/II clinical trial of AMT-060 for treating hemophilia B. uniQure N.V.
• [13] ClinicalTrials.gov (NCT02695160) Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B. U.S. National Institutes of Health.
• [14] Assessing the potential for AAV vector genotoxicity in a murine model. Correction in: Blood. 2011 June 16; 117(24): 6739.